KalVista Pharmaceuticals (KALV) Consolidated Net Income (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 12 years of Consolidated Net Income data on file, last reported at -$60.1 million in Q3 2025.

• For the quarter ending Q3 2025, Consolidated Net Income fell 48.7% year-over-year to -$60.1 million; the trailing twelve-month figure through Jul 2025 stood at -$164.4 million (down 107.85% YoY), and the FY2025 full-year result was -$183.5 million, down 248.36% from the prior year.
• Consolidated Net Income slipped to -$60.1 million in Q3 2025, from -$52.2 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $29.3 million in Q2 2024 to a low of -$60.1 million in Q3 2025.
• A 5-year average of -$33.8 million and a median of -$37.6 million in 2022 frame the typical range for Consolidated Net Income.
• Across the five-year window, Consolidated Net Income soared 196.8% in 2024 and plunged 278.07% in 2025, its largest moves.
• Tracing KALV's Consolidated Net Income over 5 years: stood at -$33.3 million in 2021, then retreated by 11.62% to -$37.2 million in 2022, then fell by 4.7% to -$39.0 million in 2023, then plunged by 33.57% to -$52.1 million in 2024, then decreased by 15.52% to -$60.1 million in 2025.
• Business Quant data shows KALV's Consolidated Net Income at -$60.1 million in Q3 2025, -$52.2 million in Q2 2025, and -$52.1 million in Q4 2024.